Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H(HK:3378)
HK$22.98-1.60 (-6.51%)
HK:3378
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H financials statements
HK$22.98
At close:-1.60 (-6.51%)
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H (3378) Income Statement
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H Income Statement
Last quarter (Q2 2019), Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H's total revenue was ¥3.48B, an increase of 7.82% from the same quarter last year. In Q2, Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H's net income was ¥167.19M. See Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 21 | Dec 20 | Dec 19 | Dec 18 | Dec 17 |
|---|---|---|---|---|---|
| ¥ 25.69B | ¥ 17.69B | ¥ 13.93B | ¥ 12.92B | ¥ 12.92B | |
| ¥ 1.38B | ¥ 1.23B | ¥ 1.26B | ¥ 1.22B | ¥ 1.20B | |
| ¥ 307.29M | ¥ 229.45M | ¥ 221.13M | ¥ 223.22M | ¥ 257.54M | |
| Depreciation and Amortization | ¥ 0.00 | ¥ 794.25M | ¥ 764.71M | ¥ 697.51M | ¥ 595.20M |
| ¥ 1.29B | ¥ 1.90B | ¥ 1.91B | ¥ 1.51B | ¥ 1.45B | |
| ¥ 1.20B | ¥ 770.54M | ¥ 759.37M | ¥ 809.02M | ¥ 855.84M | |
| ¥ -217.41M | ¥ 56.58M | ¥ 141.55M | ¥ 562.00K | ¥ 214.80M | |
| ¥ 983.82M | ¥ 827.12M | ¥ 900.92M | ¥ 809.59M | ¥ 1.07B | |
| ¥ 769.11M | ¥ 616.58M | ¥ 668.76M | ¥ 554.39M | ¥ 819.60M | |
| Per Share Metrics | |||||
| Basic EPS | ¥ 0.28 | ¥ 0.23 | ¥ 0.25 | ¥ 0.20 | ¥ 0.30 |
| Diluted EPS | ¥ 0.28 | ¥ 0.23 | ¥ 0.25 | ¥ 0.20 | ¥ 0.30 |
| Weighted Average Shares Outstanding | 2.73B | 2.73B | 2.73B | 2.73B | 2.73B |
| Weighted Average Shares Outstanding (Diluted) | 2.73B | 2.73B | 2.73B | 2.73B | 2.73B |
Currency in CNY

